Ranked in the top 9% globally in the industry, Kayentis solidifies its position as a leading provider committed to sustainability across all pillars of Corporate Social Responsibility.
Grenoble, France – November 4, 2025 – Kayentis, a global provider of electronic Clinical Outcome Assessment (eCOA), is proud to announce that it has been awarded the Silver Medal in the EcoVadis sustainability evaluation for the fourth consecutive year, reaffirming its strong commitment to responsible and ethical business practices.
This year’s achievement is particularly impressive: Kayentis has improved its score by 8 points, reaching the 91st percentile among companies in its industry. This progress reflects the company’s sustained efforts to strengthen its Corporate Social Responsibility (CSR) strategy and implement impactful initiatives across all areas assessed by EcoVadis.
Our key area of progress
EcoVadis evaluates companies on four pillars of sustainability, with Kayentis making measurable improvements in each:
- Environment: Guided by quantifiable objectives for our carbon footprint, we have integrated environmental considerations into our strategic decision-making.
- Labor and Human Rights: We have reinforced our inclusive HR policies, ensured continuous training is accessible to all employees, and supported internal mobility to foster professional growth and equal opportunities. We also engage with the community through partnerships with local organizations and patient associations to promote social responsibility.
- Ethics: We have strengthened compliance frameworks and transparency in our operations.
- Sustainable Procurement: Through active participation in client audits and ongoing stakeholder dialogue, our CSR governance encompasses transparency in internal and external processes, regulatory compliance, business ethics, and collaborative engagement.
“I am delighted that the efforts we have made at Kayentis over the past five years are clearly reflected in this EcoVadis rating,” said Laure Mallet, CSR Manager at Kayentis. “But we don’t intend to stop there! This evaluation and our strong convictions motivate us to keep pushing forward and to build an even more ambitious sustainability strategy and actions.”
A key milestone for the clinical research industry
This award represents more than recognition for Kayentis, it reflects the growing commitment across the clinical research sector to embed Environmental, Social, and Governance (ESG) principles into every aspect of operations. As highlighted in the Joint CEO Letter to the Industry, ESG is no longer optional; it is a strategic necessity to ensure trust, resilience, and innovation in global clinical trials.
By ranking in the top 9% of companies in its industry worldwide, Kayentis demonstrates leadership in answering this need—not just in response to the call, but through proactive action. We launched a carbon-neutral program for clinical trials as early as 2020, underscoring our long-standing commitment to sustainability and ethical practices.
This award reinforces our belief that advancing ESG is essential for shaping the future of clinical research and delivering value to patients, partners, and society.
About Kayentis
Kayentis, a global leader in eCOA and decentralized clinical trial solutions, empowers pharma, biotech and CROs to streamline data collection in clinical trials, enhancing simplicity, efficiency and data quality. Since 2005, Kayentis has spearheaded clinical development, specializing in eCOA solutions across phases I-IV in over 200 indications across more than 20 therapeutic areas. Adapting to the changing landscape, Kayentis is now offering a comprehensive suite of services to support science-driven and patient-centric clinical research, with operational capabilities across the US, Europe and Asia.
Contact
communication@kayentis.com
